Objectives: According to current guidelines, either immunohistochemistry (IHC) or in situ hybridization (ISH) can be used to determine human epidermal growth factor receptor 2 (Her2/neu) status in breast carcinoma. While the guidelines explicitly delineate result interpretation, there is no consensus on the most appropriate testing algorithm.
The human epidermal growth factor receptor 2 protein (Her2/neu) is a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene located on the long arm of chromosome 17 (17q12). 1 The genetic amplification and/or protein overexpression of Her2/neu in neoplastic cells appears to be an important factor in tumor biology and can be seen in up to 20% of primary breast carcinomas, as well as subsets of ovarian, gastric, colorectal, pancreatic, and endometrial carcinomas. 2 Not only is Her2/neu status an important predictive and adverse prognostic factor in breast cancer, but also its accurate determination is critical for planning treatment since its positivity enables targeted molecular therapies to be used. Inaccuracies in determining Her2/neu status are detrimental, as false negatives would preclude patients from potentially effective treatment, while false positives could expose them to unneeded therapies with potentially significant side effects as well as create an unnecessary economic burden. 3 Guidelines for reporting Her2/neu status were initially conceived in 2007 by the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP), with revisions in 2013. 4 While there are many methods to assess Her2/neu status, the newest ASCO/CAP guidelines only approve either immunohistochemistry (IHC) or in situ hybridization (ISH), with the latter including any of chromogenic ISH (CISH), silver ISH (SISH), or fluorescence ISH (FISH) methodologies for visualization. 4 There are advantages and disadvantages to all testing modalities, and each may be significantly affected by preanalytic and analytic factors.
The implications of the changes made in the 2013 recommendations are not entirely clear. For IHC, the number of cells required to exhibit strong, complete membranous staining for a positive result was decreased from 30% to 10%. In addition, the guidelines more explicitly described the requirements for equivocal results. 4 While one may assume that this change would potentially increase the number of Her2/neu-positive patients identified, a recent study showed that there was a significant increase in tumors classified as equivocal, while there was no increase in positive tumors. 6 Therefore, the ultimate result could be an increase in reflex testing. Similarly, the guidelines for reporting ISH results were updated to take into account not only the ratio of HER2 to chromosome enumeration probe 17 (CEP17) copy number but also average HER2 copy number. Again, at face value, these changes may seem to increase those cases classified as positive, but recent studies have showed that the greatest increase is in the number of equivocal cases. [7] [8] [9] [10] [11] In addition, a few studies have shown that the changes in the updated guidelines have had the practical result of increasing discordance between IHC and FISH results. 12 It seems as if this discordance may be due to genetic or chromosomal alterations of the area of chromosome 17 highlighted by the CEP17 probe, thus affecting the HER2/ CEP17 ratio. 13 However, true polysomy 17, with amplification of the entire chromosome, appears to be a rare event in breast cancer, and therefore, in these instances, the use of alternative probes other than CEP17 for determining copy number ratios can be useful. 14, 15 At our institution, Her2/neu is tested by both IHC and FISH using dual HER2 and CEP17 probes on all newly diagnosed breast cancers. In addition, if equivocal FISH results are obtained, ancillary testing using an alternative chromosome 17 probe is used. While performing dual testing has economic drawbacks and is more labor intensive, the use of both IHC and FISH ensures that no Her2/neupositive patients who could benefit from targeted therapies are missed. Here, we assess the concordance between the two methods and determine how frequently Her2/neuamplified tumors would have been missed had a reflex testing strategy been used where testing by the second modality was performed only in equivocal cases.
Materials and Methods

Case Cohort
The study was reviewed by the institutional review board at the University of California San Diego and was certified as exempt because it is research involving retrospective review of deidentified data. Consecutive cases of invasive breast cancer that underwent definitive surgical excision at a tertiary care academic medical center between June 2014 and December 2015 were collected. In all cases, both IHC and FISH were performed, with specific details described below. If the initial diagnosis on the core biopsy specimen was made at our institution, then both IHC and FISH were performed on the biopsy specimen. Unless there was histopathologic discordance or the patient received neoadjuvant chemotherapy, the testing was not repeated on the definitive excision. In situations where the patient had been initially diagnosed at an outside institution and referred to our institution for definitive management, the outside slides were reviewed prior to surgery, but the Her2/neu testing was not repeated on the initial biopsy specimen. In these cases, our ancillary testing for Her2/neu using both IHC and FISH was performed only on the definitive excision.
In all situations, specimens were handled according to the 2013 ASCO/CAP guidelines, including fixation in 10% neutral buffered formalin occurring within 1 hour and total fixation time between 6 and 72 hours. Immunohistochemical and FISH results, in addition to patient demographic data and pathologic diagnosis, stage, and grade of the tumor, were extracted from the final pathology reports and the medical records.
Immunohistochemical Analysis
For IHC, staining was performed on 4-lm-thick formalin-fixed, paraffin-embedded tissue sections using a Ventana automated platform (rabbit monoclonal antibody, clone 4B5; Roche/Ventana Medical Systems, Tucson, AZ). Standardized immunohistochemical protocols were used with appropriate positive controls. Results were interpreted by a staff pathologist and reported using ASCO/CAP 2013 criteria (Supplementary Figure 1 ; all supplemental materials can be found at American Journal of Clinical Pathology online).
FISH Analysis
FISH was performed on formalin-fixed, paraffinembedded tissue sections using dual-color HER2/CEP17 probes (PathVysion Her2/neu DNA Probe Kit; Abbott Molecular, Abbott Park, IL). If equivocal results were obtained, then dual-color probes for HER2 and lissencephaly gene 1 (LIS1) at chromosome 17p13 were used and the analysis was repeated. Results were interpreted by a cytogeneticist (M.D.'A.) and reported using ASCO/CAP 2013 criteria (Supplementary Figure 2) . 
Statistical Analysis
Results
From June 2014 through December 2015, a total of 369 separate invasive breast carcinomas from 351 patients were definitively excised. The distribution of patient demographic data and histologic findings of the tumors are summarized in Table 1 . Overall, 60 (17.1%) of the 351 patients and 61 (16.5%) of the 369 tumors were Her2/neu positive. For the tumor T and N staging, the discrepancy in the number of tumors is due to the fact that if a patient had tumors in separate breasts, then each side was staged separately, but multiple tumors within the same breast were staged as multifocal and only given one T and N stage. Also, if the patient received neoadjuvant chemotherapy, the staging was following chemotherapy; hence, multiple patients were staged as no residual tumor or only in situ disease remaining (ypT0 or ypTis, respectively).
Her2/neu dual testing was performed on 156 core biopsy specimens with a concordance rate of 98.1% (Supplementary Table 1 ) and was performed on 247 definitive excision specimens with a concordance rate of 96.3% (Supplementary  Table 2 ). In one case, FISH could not be performed, and therefore this case was removed from analysis. There was no significant difference in the immunohistochemical or FISH results when comparing core biopsy specimens vs definitive excisions (P ¼ .08 for IHC and P ¼ .62 for FISH).
Thirty-four of the tumors had Her2/neu dual testing performed on both the initial biopsy specimen and the definitive excisions for reasons that included neoadjuvant chemotherapy treatment or histopathologic discordance. After taking into account cases that were tested twice to prevent double counting, the overall results for all tumors examined are shown in Table 2 . Of the 368 tumors, there were nine discordant cases. Eight were positive by FISH but negative by IHC, while one was negative by FISH but positive by IHC. The overall concordance rate between IHC and FISH was calculated to be 97.6%, which is within the threshold allowed by the ASCO/ CAP guidelines of 95%.
The discordant cases that had discrepant IHC and FISH results on the biopsy specimen or the definitive excision are shown in Table 3 . Two cases (cases 6 and 8) had a previous biopsy at an outside institution that was positive for Her2/neu by IHC, and the patient had previously received neoadjuvant chemotherapy with an anti-Her2/neu antibody, so there would be no change in management. Of the rest, six Her2, human epidermal growth factor receptor 2.
a For tumor T and N staging, the discrepancy in the number of tumors is due to the fact that multiple primary tumors in the same breast were given only one T and N stage and a descriptor of "multifocal," whereas bilateral tumors in a patient were each staged separately. (1.7%) of the 351 patients were reclassified as being Her2/ neu positive after a negative IHC result (Table 3 , bold cases), while only one case with a positive IHC result (3þ) was found to be HER2 nonamplified by FISH. Had a reflex strategy been used, these six patients would have been missed. Since a total of only 60 Her2/neu-positive patients were identified in this study, a reflex strategy could potentially be missing 10% of all Her2/neu-amplified cases. Interestingly, in three of the cases where the patient was reclassified as Her2/neu positive (cases 1, 2, and 5), the alternative LIS1 probe was required to demonstrate a HER2 amplification ratio classified as positive, since using the standard CEP17 probe alone was equivocal. Had the alternative probe not been used, these FISH results would have been equivocal, and the patient would not have been classified as Her2/neu positive. Because there is no gold standard for Her2/neu status determination, the paired sensitivities of the IHC and FISH tests were compared using McNemar's test, which allows for statistical comparison of paired nominal data. It was demonstrated that the FISH test in our case cohort was able to identify significantly more Her2/neu-positive cases than IHC (Supplementary Table 3 ). Even without the use of an alternative probe for chromosome 17, which increases sensitivity of FISH, testing by FISH still identified significantly more Her2/neu-positive cases than IHC (Supplementary Table 4 , P ¼ .0005).
Discussion
While adequate concordance was demonstrated, there continues to be a small but persistent discrepancy rate between Her2/neu status as determined by IHC and FISH. The discordant cases seen in this study are mostly those that are scored as negative (0 or 1þ) by IHC but are positive by FISH. Performing testing by both modalities allows for inclusion of additional patients for Her2/neu-targeted therapy that may not otherwise be eligible. Therefore, a reflex strategy based on IHC results may potentially deny needed therapy for a small cohort of patients. In this study, six patients were identified who were Her2/neu positive by FISH after a negative result by IHC, affecting their clinical course. Since only a total of 60 Her2/neu-positive patients were identified in the patient cohort, had only a reflex strategy been performed, 10% of the Her2/neu-positive patients would have been missed.
Interestingly, four patients with a discordant result on the definitive excision had been previously called Her2/neu positive on initial biopsy and had completed neoadjuvant chemotherapy with Her2/neu-targeted therapy. Two of the patients had a previous biopsy at an outside institution that was positive by IHC only, while the other two patients had a previous biopsy at our own institution that showed a concordant positive Her2/neu result by both IHC and FISH. While there would be no change in management for these four patients, the emergence of the discordance by IHC and FISH after Her2/neu-targeted therapy suggests that it is likely due to the effect of the therapy. Although the reported results have not been entirely congruent, several studies have previously shown that neoadjuvant chemotherapy may alter Her2/neu expression in breast cancers as assessed by IHC without affecting results as determined by FISH. [16] [17] [18] [19] It is also of interest that in three of the cases where the patient was reclassified as being Her2/neu positive, the alternative LIS1 probe was required to demonstrate a HER2 amplification ratio that could be classified as positive since using the standard CEP17 probe alone was equivocal. This study highlights the importance of using alternative probes to maximize sensitivity of determining HER2 amplification. Our study is broadly in line with recent others that have highlighted the utility of alternative probes in resolving FISH-equivocal cases. [20] [21] [22] An alternative interpretation of the entire study as a whole, however, may be that while FISH is capable of identifying more Her2/neu-positive cases, especially with the use of alternative chromosome 17 probes, it could be that the threshold for calling Her2/neu positivity is actually too sensitive and may be introducing false-positive results. Further study to determine the outcomes and efficacy of Her2/neu-targeted treatment for this particular subset of patients may ultimately be necessary. While sensitive and accurate identification of Her2/neu patients is important for the clinical course of patients with breast cancer, we recognize that performing dual testing on every case of breast carcinoma may not be practical. However, an alternative testing algorithm that prioritizes FISH over IHC could be considered. While our data show that the commonly used IHC reflex strategy would have missed six patients (10% of Her2/neu-positive patients), an algorithm that uses HER2/CEP17 FISH, followed by reflex testing with an alternative chromosome 17 probe such as LIS1 if an equivocal result is obtained, would have missed only two patients (3% of Her2/neu-positive patients). Such algorithms could be considered to balance sensitivity with workload and expense.
In addition, newer commercially available approaches enable pathologists to examine Her2/neu protein expression status and gene amplification on a single slide using a combination of IHC and SISH. 23 Such technology may enable economically feasible routine dual testing in the future. Moreover, other orthogonal methods for determining Her2/ neu status are currently being investigated. For example, messenger RNA expression levels can be measured using quantitative reverse transcriptase polymerase chain reaction, a technique that was shown to be cost-effective and reliable with paraffin-embedded tumors, and adequate concordance was demonstrated with both FISH and IHC. 24 In addition, this method would likely be less labor-intensive and would also reduce the need for expert interpretation that may suffer from interobserver variability. Despite these benefits, however, this technique is currently not endorsed by the ASCO/CAP guidelines, as the update committee in 2013 believed that additional evidence of its utility was warranted. 4 As technology further progresses, the future categorization of breast cancer is likely to be according to gene expression subtypes (luminal A, luminal B, Her2-like, and basal-like), as these seem to give more prognostic information and more information for determining treatment strategy. Until these are in widespread use, however, we must currently use surrogate markers, including hormone receptor expression and Her2/ neu status. Therefore, the factors presented here should be considered as testing guidelines are formulated and the costbenefit analyses of various testing approaches are assessed.
